Literature DB >> 26483273

Development and psychometric analysis of the Duchenne muscular dystrophy Functional Ability Self-Assessment Tool (DMDSAT).

Erik Landfeldt1, Anna Mayhew2, Michelle Eagle2, Peter Lindgren3, Christopher F Bell4, Michela Guglieri2, Volker Straub2, Hanns Lochmüller2, Katharine Bushby2.   

Abstract

The objective of this study was to describe the development and initial psychometric analysis of the UK English version of the Duchenne muscular dystrophy Functional Ability Self-Assessment Tool (DMDSAT), a patient-reported outcome (PRO) scale designed to measure functional ability in patients with Duchenne muscular dystrophy (DMD). Item selection was made by neuromuscular specialists and a Rasch analysis was performed to understand the psychometric properties of the DMDSAT. Instrument scores were also linked to cost of illness and health-related quality of life data. The administered version, completed by 186 UK patient-caregivers pairs, included eight items in four domains: Arm function, Mobility, Transfers, and Ventilation status. These items together successfully operationalized functional ability in DMD, with excellent targeting and reliability (Person Separation Index: 0.95; Cronbach's α: 0.93), stable item locations, and good fit to the Rasch model (mean person/item fit residual: -0.21/-0.44, SD: 0.32/1.28). Estimated item difficulty was in excellent agreement with clinical opinion (Spearman's ρ: 0.95) and instrument scores mapped well onto health economic outcomes. We show that the DMDSAT is a PRO instrument fit for purpose to measure functional ability in ambulant and non-ambulant patients with DMD. Rasch analysis augments clinical expertise in the development of robust rating scales.
Copyright © 2015 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Costs; Functional ability; Patient-reported outcome; Rasch analysis; Rating scale; Utilities

Mesh:

Year:  2015        PMID: 26483273     DOI: 10.1016/j.nmd.2015.09.012

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  7 in total

1.  Pain characteristics among individuals with Duchenne muscular dystrophy according to their clinical stage.

Authors:  Aram Kim; Mina Park; Hyung-Ik Shin
Journal:  BMC Musculoskelet Disord       Date:  2022-06-04       Impact factor: 2.562

2.  Factors associated with the health-related quality of life among people with Duchenne muscular dystrophy: a study using the Health Utilities Index (HUI).

Authors:  Shelagh M Szabo; Ivana F Audhya; Basia Rogula; David Feeny; Katherine L Gooch
Journal:  Health Qual Life Outcomes       Date:  2022-06-11       Impact factor: 3.077

3.  Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis.

Authors:  Erik Landfeldt; Lars Alfredsson; Volker Straub; Hanns Lochmüller; Katharine Bushby; Peter Lindgren
Journal:  Pharmacoeconomics       Date:  2017-02       Impact factor: 4.981

4.  Priorities when deciding on participation in early-phase gene therapy trials for Duchenne muscular dystrophy: a best-worst scaling experiment in caregivers and adult patients.

Authors:  Ryan S Paquin; Ryan Fischer; Carol Mansfield; Brennan Mange; Katherine Beaverson; Annie Ganot; Amy Strong Martin; Carl Morris; Colin Rensch; Valeria Ricotti; Leo J Russo; Alesia Sadosky; Edward C Smith; Holly L Peay
Journal:  Orphanet J Rare Dis       Date:  2019-05-09       Impact factor: 4.123

5.  Characterizing health state utilities associated with Duchenne muscular dystrophy: a systematic review.

Authors:  Shelagh M Szabo; Ivana F Audhya; Daniel C Malone; David Feeny; Katherine L Gooch
Journal:  Qual Life Res       Date:  2019-12-06       Impact factor: 4.147

6.  Adapting traditional content validation methods to fit purpose: an example with a novel video assessment and training materials in Duchenne muscular dystrophy (DMD).

Authors:  Michelle K White; Mindy Leffler; Kaitlin Rychlec; Chris Jones; Christine McSherry; Linsey Walker; Mark Kosinski
Journal:  Qual Life Res       Date:  2019-07-13       Impact factor: 4.147

7.  Patient-led development of digital endpoints and the use of computer vision analysis in assessment of motor function in rare diseases.

Authors:  Elisa Ferrer-Mallol; Clare Matthews; Madeline Stoodley; Alessandra Gaeta; Elinor George; Emily Reuben; Alex Johnson; Elin Haf Davies
Journal:  Front Pharmacol       Date:  2022-09-12       Impact factor: 5.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.